Flt-3/Flk-2 Antibody (8H5): sc-101343

Flt-3/Flk-2 Antibody (8H5) is a mouse monoclonal IgG1 antibody that detects Flt-3/Flk-2 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), and immunofluorescence (IF). Flt-3/Flk-2, also known as stem cell tyrosine kinase (STK-1), plays a crucial role in hematopoiesis as a member of the type III receptor tyrosine kinase family, which includes other important receptors like Kit and PDGF. Flt-3/Flk-2 is primarily expressed in CD34+ hematopoietic stem and progenitor cells, where anti-Flt-3/Flk-2 antibody (8H5) can detect its function as a growth factor receptor influencing cell proliferation and differentiation. Flt-3/Flk-2′s location in these specific cell types highlights its involvement in regulating hematopoietic stem cell maintenance and blood cell lineage development. Flt-3/Flk-2 undergoes post-translational modifications, including phosphorylation, which are essential for activation and signaling capabilities. These modifications can impact receptor function and interactions with downstream signaling pathways, making Flt-3/Flk-2 monoclonal antibody (8H5) valuable for understanding hematological disorders and potential therapeutic interventions. Flt-3/Flk-2 (8H5) antibody provides reliable detection and characterization, supporting research in stem cell biology and related fields.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Flt-3/Flk-2 Antibody (8H5) References:

1. Use of matrix metalloproteinase (MMP)-9 knockout mice demonstrates that MMP-9 activity is not absolutely required for G-CSF or Flt-3 ligand-induced hematopoietic progenitor cell mobilization or engraftment.  |  Robinson, SN., et al. 2003. Stem Cells. 21: 417-27. PMID: 12832695
2. FLT-3 aberrations in acute promyelocytic leukaemia: clinicopathological associations and prognostic impact.  |  Au, WY., et al. 2004. Br J Haematol. 125: 463-9. PMID: 15142116
3. Systemic mobilization of antigen presenting cells, with a chimeric Flt-3 and G-CSF receptor agonist, during immunization of Macaca mulatta with HIV-1 antigens is insufficient to modulate immune responses or vaccine efficacy.  |  Koopman, G., et al. 2005. Vaccine. 23: 4195-202. PMID: 15896883
4. Expression of c-kit, Flk-1, and Flk-2 receptors in benign and malignant tumors of follicular epithelial origin.  |  Kung, SP., et al. 2006. J Chin Med Assoc. 69: 74-9. PMID: 16570574
5. FLT-3 expression and function on microglia in multiple sclerosis.  |  DeBoy, CA., et al. 2010. Exp Mol Pathol. 89: 109-16. PMID: 20566414
6. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation.  |  Ravandi, F., et al. 2013. Blood. 121: 4655-62. PMID: 23613521
7. Enhancing Antiproliferative Activity and Selectivity of a FLT-3 Inhibitor by Proteolysis Targeting Chimera Conversion.  |  Burslem, GM., et al. 2018. J Am Chem Soc. 140: 16428-16432. PMID: 30427680
8. A quantitative method for detection of circulating fms related tyrosine kinase 3 (FLT-3) in acute myeloid leukemia (AML) patients.  |  Cook, KD., et al. 2019. J Immunol Methods. 470: 55-58. PMID: 31034878
9. PCW-A1001, AI-assisted de novo design approach to design a selective inhibitor for FLT-3(D835Y) in acute myeloid leukemia.  |  Jang, SH., et al. 2022. Front Mol Biosci. 9: 1072028. PMID: 36504722
10. FLT-3 ligand and marrow stroma-derived factors promote CD3gamma, CD3delta, CD3zeta, and RAG-2 gene expression in primary human CD34+LIN-DR- marrow progenitors.  |  Gaffney, PM., et al. 1998. Blood. 91: 1662-70. PMID: 9473232

The preferred Flt-3/Flk-2 antibody is Flt-3/Flk-2 Antibody (SF1.340): sc-19635.